Articles From: Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis to ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola


KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics Awarded "Best Pipeline 2014" by Animal Pharm investment picks
Represents a Novel Approach to Treating B-cell Lymphoma in Dogs KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics Granted Full License for AT-004 by USDA investment picks
2014/11/4
Conference Call and Webcast scheduled for November 11, 2014, 8:30 a.m. ET KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics Inc. to Report Third Quarter Financial Results investment picks
Product is being developed to treat post-surgical pain in dogs KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics Initiates Pivotal Study for AT-003 investment picks
2014/11/10
- Conference Call Tomorrow, November 11, 2014, 8:30 a.m. Eastern Time - KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics Reports Third Quarter 2014 Results investment picks
KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics to Present at Jefferies Global Healthcare Conference investment picks
KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics to Present at the 2014 Animal & Dental Health Summit investment picks
UNIONDALE, N.Y., Nov.
Sign-up for Arbor Realty Trust Declares Preferred Stock Dividends investment picks
Third Quarter Highlights: Net income of $63.4 million, or $1.26 per diluted common share FFO of $65.5 million, or $1.30 per diluted common share and FFO of $7.4 million, or $0.15 per diluted common share excluding the recognition of a $58.1 million non-cash gain 1 Recognized a $58.1 million gain related to the 450 West 33rd Street transaction resulting in a $1.15, or 15%, increase in GAAP book value per common share to $8.81 Declares a cash dividend of $0.13 per share of common stock Issued $39.2 million of senior unsecured notes UNIONDALE, N.Y., Nov.
Sign-up for Arbor Realty Trust Reports Third Quarter 2014 Results and Declares Common Stock Dividend investment picks
UNIONDALE, N.Y., Oct.
Sign-up for Arbor Realty Trust Schedules Third Quarter 2014 Earnings Conference Call investment picks
http://media.marketwire.com/attachments/201410/281332_ARC-Linear-Lockup-JPG300pxwide.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160647&ProfileId=051205&sourceType=1 WALNUT CREEK, CA --
Sign-up for ARC Document Solutions Announces Refinancing of 6.25% Term B Loan; Estimated Annual Interest Savings In Excess Of $5 Million investment picks
http://media.marketwire.com/attachments/201410/281332_ARC-Linear-Lockup-JPG300pxwide.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157033&ProfileId=051205&sourceType=1 WALNUT CREEK, CA --
Sign-up for ARC Document Solutions Reports Results for Third Quarter 2014 investment picks
DELAND, Fla.
Sign-up for ARC Group Worldwide CEO Featured Panelist at "Make it in America" investment picks
DELAND, Fla.
Sign-up for ARC Group Worldwide Posting of Company Presentation investment picks
2014/11/12
DELAND, Fla.
Sign-up for ARC Group Worldwide Reports Record Sales and Gross Profit investment picks
NEW YORK, Nov.
Sign-up for Arc Logistics Partners LP Announces Third Quarter 2014 Results investment picks
Report Looks Forward to 2015 and Provides Insights for Air Travelers ARLINGTON, Va.
Sign-up for ARC Partners with Expedia, Inc. to Produce Air Travel Trends Study investment picks
2015/1/7
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. Announces Bought Deal Financing and Reduced 2015 Capital Program investment picks
2015/1/7
CALGARY , Jan.
Sign-up for ARC Resources Ltd. Announces Reduced 2015 Capital Program investment picks
2015/1/16
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. Confirms February 17, 2015 Dividend Amount investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the activation of the first GENETIC-AF clinical trial site in Canada.
Sign-up for Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions.
Sign-up for ARCA biopharma Announces Management Transitions investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.
Sign-up for ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis to ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent